Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Pheniramine Aminosalicylate Overdosage:Reversal of Delirium & Choreiform Movements with Tacrine Treatment
Arch Neurol 34:313, Mendelson,G.,et al, 1977
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Managing Acute Organophosphorus Pesticide Poisoning
BMJ 334:629-634, Roberts,D.M.&Aaron,C.K., 2007
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Positive Response to Edrophonium in Patients with Neurotoxic Envenoming by Cobras (NAJA NAJA PHILIPPINENIS)
NEJM 315:1444-1448, Watt,G.,et al, 1986
Memory Enhancement with Oral Physostigmine in Alzheimer's Disease
NEJM 308:720-721, Thal,L.J.,et al, 1983
Enhancement Of Memory By Physostigmine
NEJM 301:946, Davis,K.L.,et al, 1979